NCT02713022

Brief Summary

The investigators want to find a better way to predict the risk of having fatty tissue inflammation by using a different approach to finding out body fat composition. In this study, the investigators want to estimate the body fat composition using a DEXA scan. DEXA stands for dual energy X-ray absorptiometry. It is the standard and established test to determine bone mineral density (how strong the bones are) to diagnose osteoporosis. This test can also be used to determine the body composition including percent body fat and lean mass. The investigators will compare the participants DEXA scan results for body fat composition to the inflammation found in the breast tissue from the mastectomy to see if there is a relationship. If successful, this may help us predict which patients may be at risk for breast cancer in the future. In addition, the investigators will compare the participants DEXA scan results for body fat composition and inflammation found in the fat tissue from the mastectomy or prostatectomy to the level of exercise activity as measured by a short questionnaire to see if there is a relationship. The investigators will also measure the participants waist to hip ratio. Finally, at the time the participant has blood drawn for their standard presurgical testing, the investigators will also test the blood for prediabetes using a blood test called hemoglocin A1c. The investigators will also measure for the participants waist to hip ratio, and a Hgb A1c blood drawn will be take at the time of presurgical testing. If not feasible, Hgb A1c can be drawn at a separate visit prior to the DEXA scan. If successful, this may help us predict which patients may be at risk for breast cancer in the future.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
202

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Nov 2015

Longer than P75 for all trials

Geographic Reach
1 country

9 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 4, 2015

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

March 11, 2016

Completed
7 days until next milestone

First Posted

Study publicly available on registry

March 18, 2016

Completed
7.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 7, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 7, 2023

Completed
Last Updated

November 8, 2023

Status Verified

November 1, 2023

Enrollment Period

8 years

First QC Date

March 11, 2016

Last Update Submit

November 7, 2023

Conditions

Keywords

DEXA Scan15-235

Outcome Measures

Primary Outcomes (2)

  • fat percentage

    as measured by DEXA

    1 year

  • presence of White Adipose Tissue Inflammation (WATi )

    as measured by DEXA

    1 year

Study Arms (2)

Breast Cancer

DEXA scan will be carried out 1 to 30 days prior to mastectomy. Patients will also complete the Godin Leisure Time Exercise Questionnaire (GLTEQ) and their waist to hip ratio will be measured.

Device: DEXA ScanBehavioral: Godin Leisure Time Exercise Questionnaire (GLTEQ)

Prostate Cancer

DEXA scan will be carried out 1 to 30 days prior to radical prostatectomy. Patients will also complete the Godin Leisure Time Exercise Questionnaire (GLTEQ) and their waist to hip ratio will be measured.

Device: DEXA ScanBehavioral: Godin Leisure Time Exercise Questionnaire (GLTEQ)

Interventions

DEXA ScanDEVICE
Breast CancerProstate Cancer
Breast CancerProstate Cancer

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

This study is open to patients undergoing prophylactic or therapeutic mastectomy or radical prostatectomy at MSKCC. Patients will be identified and recruited from the Breast Service at and Plastics and Reconstructive Surgery Clinics MSKCC and approached at the time of initial surgical consultation.

You may qualify if:

  • Age ≥ 18
  • Female
  • All BMIs
  • Patients undergoing mastectomy at MSKCC (i.e. Nipple-sparing mastectomy, skin-sparing mastectomy, simple mastectomy, modified radical mastectomy, radical mastectomy); mastectomy may be either prophylactic or therapeutic. OR
  • Patients undergoing hysterectomy at MSKCC
  • History of prior breast surgeries/procedures is acceptable

You may not qualify if:

  • Pregnancy (confirmed or suspected);
  • Inability to lay supine on equipment table and maintain the position for the necessary time;
  • Weight superior to the maximum allowed by the DEXA machine (over 350 lbs or 158 kg);
  • Greater than 10% baseline weight loss in the past year;
  • Planned surgical procedure is not a Mastectomy (i.e. breast conservation surgery or other non-mastectomy procedure; such as lumpectomy) or hysterectomy
  • Metastatic cancer
  • History of Wasting Syndromes or Cachexia
  • Use of daily NSAIDs, aspirin, or steroids (other than inhaled or topical) within 30 days of surgery
  • Use of neoadjuvant systemic or radiation therapy.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (9)

Waters Corporation (Data Analysis Only)

Milford, Massachusetts, 01757, United States

Location

Memorial Sloan Kettering Cancer Center (Consent Only)

Basking Ridge, New Jersey, United States

Location

Memorial Sloan Kettering Monmouth (Consent Only)

Middletown, New Jersey, 07748, United States

Location

Memorial Sloan Kettering Bergen (Consent only)

Montvale, New Jersey, 07645, United States

Location

Memorial Sloan Kettering Cancer Center @ Commack (Consent Only)

Commack, New York, 11725, United States

Location

Memorial Sloan Kettering Westchester (Consent Only)

Harrison, New York, 10604, United States

Location

Weill Medical College of Cornell University (Data and Specimen Analysis Only)

New York, New York, 10021, United States

Location

Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States

Location

Memorial Sloan Kettering Nassau (Consent only)

Uniondale, New York, 11553, United States

Location

Related Links

MeSH Terms

Conditions

Breast NeoplasmsProstatic Neoplasms

Interventions

Absorptiometry, Photon

Condition Hierarchy (Ancestors)

Neoplasms by SiteNeoplasmsBreast DiseasesSkin DiseasesSkin and Connective Tissue DiseasesGenital Neoplasms, MaleUrogenital NeoplasmsGenital Diseases, MaleGenital DiseasesUrogenital DiseasesProstatic DiseasesMale Urogenital Diseases

Intervention Hierarchy (Ancestors)

RadiographyDiagnostic ImagingDiagnostic Techniques and ProceduresDiagnosisDensitometryPhotometryChemistry Techniques, AnalyticalInvestigative Techniques

Study Officials

  • Neil Iyengar, MD

    Memorial Sloan Kettering Cancer Center

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 11, 2016

First Posted

March 18, 2016

Study Start

November 4, 2015

Primary Completion

November 7, 2023

Study Completion

November 7, 2023

Last Updated

November 8, 2023

Record last verified: 2023-11

Locations